RxDoctor Payments Data

Bertha Fonseca, MD

Neurology · Coral Gables, FLNPI 1851592729

Payments from drug & device makers

$370,967in general payments, 2019–2025

Across 739 payments — averaging $501.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$153K
  • EMD Serono, Inc.$115K
  • Amgen$38K
  • E.r. Squibb & Sons, L.L.C.$16K
  • Sanofi$15K
  • Bristol Myers Squibb$11K
  • plus $24K from 19 others

What the payments were for

  • Consulting fees$24,5497%
  • Speaking & faculty fees$317,92486%
  • Travel & lodging$14,0574%
  • Food & beverage$14,3174%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$370,967 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$40,243
Medicare patients
126
Services billed
2,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate64$410,427
Kesimpta PenOfatumumab36$334,126
VumerityDiroximel Fumarate32$313,446
AubagioTeriflunomide32$294,637
Rebif RebidoseInterferon Beta-1a/Albumin23$266,146
GilenyaFingolimod Hcl21$247,212
RebifInterferon Beta-1a/Albumin12$146,017
TecfideraDimethyl Fumarate12$107,649
Plegridy PenPeginterferon Beta-1a12$102,688
AmpyraDalfampridine21$96,594
Teriflunomide24$94,182
GlatopaGlatiramer Acetate27$57,500
Memantine Hcl ErMemantine Hcl129$24,436
MyrbetriqMirabegron52$22,948
Glatiramer Acetate11$17,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tecfidera$152,893$421,09544 claims
Teva Pharmaceuticals USA, Inc.Copaxone$8,006$410,42764 claims
SanofiAubagio$14,546$294,63732 claims
NovartisGilenya$9,955$247,21221 claims
EMD Serono, Inc.Rebif$114,593$146,01712 claims
Acorda Therapeutics, IncAmpyra$80$96,59421 claims
PfizerLyrica$26$9,81311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →